MedPath

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia

7 months ago1 min read
Dr. Jorge E. Cortes provides a comprehensive overview of the 5-year follow-up results from the Phase 2 OPTIC study, showcasing the long-term efficacy, safety, and mutational analysis of ponatinib in patients with chronic-phase chronic myeloid leukemia, including outcomes related to dose modifications and mutation evolution.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related News

LUMEVOQ Gene Therapy Shows Sustained Vision Improvement in LHON Patients After 5 Years

Lenadogene Nolparvovec Shows Sustained Vision Improvement in LHON Patients After 5 Years

Risk Management Strategies Improve Long-Term Safety Profile of Ponatinib in CML and ALL

Olverembatinib Shows Promise as Second-Line Therapy for Chronic Phase CML

PolyActiva's PA5108 Glaucoma Implant Demonstrates Promising IOP Reduction in Phase 2 Trial

Nanoscope's MCO-010 Gene Therapy Shows Sustained Vision Improvement in Retinitis Pigmentosa Trial

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia

Tailored TKI Dosing Strategies Improve Outcomes in Chronic Myeloid Leukemia

Ponatinib Dose-Ranging Study Shows Efficacy in Chronic-Phase CML Patients

Final 5-Year Results of the Phase 2 PACE Trial for CML and Ph+ ALL Patients

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.